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Abstract Indacaterol is an inhaled, ultra–long-acting
b2-agonist that provides 24-h bronchodilation with once-
daily dosing in patients with chronic obstructive pulmonary
disorder. This study evaluated the pharmacokinetics,
safety, and tolerability of multiple daily inhaled doses of
indacaterol 150 or 300 lg once daily in healthy Chinese
volunteers. This was a single-center, randomized, double-
blind, multiple-dose, parallel-group study, placebo-con-
trolled trial including two doses of indacaterol: 150 and
300 lg. Serum indacaterol was quantified using high-per-
formance liquid chromatography-mass spectrometry with a
lower limit of quantification of 0.01 ng/mL. The pharma-
cokinetic parameters were analyzed using non-compart-
mental analysis and included Cmax, Tmax, and AUC0–24h on
Day 1 and AUC0–24h,ss, Cmax,ss, Cmin,ss, Cav,ss, Tmax,ss, T1/2,
T1/2,acc, CL/F, Vz/F, and Racc on Day 14 (after repeated
once-daily doses). Safety analyses were recorded using
physical examination, biochemical tests, and ECG. Ind-
acaterol steady state was achieved after 12–14 days of
daily dosing. The mean effective half-life of indacaterol
(based on drug accumulation at steady state) was 33.9 and
35.8 h for 150 and 300 lg, respectively. Systemic exposure
to indacaterol increased 1.27 and 1.34-fold between the
150- and 300-lg doses on Day 1 (first dose) and Day 14
(repeated dose), respectively. Indacaterol 150 and 300 lg
were safe and well tolerated in these volunteers. The
pharmacokinetics of multiple inhaled doses of indacaterol
150 and 300 lg (for 14 days) were consistent with mod-
erate systemic accumulation at steady state after repeated
once-daily inhalation in healthy Chinese volunteers.
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1 Introduction
Chronic obstructive pulmonary disease (COPD) is cur-
rently the fourth leading cause of death in the world and is
estimated to rank fifth by 2020 in burden of disease
worldwide (GOLD 2013). It is also an increasing public
health concern in China (Fang et al. 2011). In a nationwide
cross-sectional survey, the prevalence of COPD in China
was found to be 8.2 % in people aged 40 years or older
(Zhong et al. 2007).
Inhaled bronchodilators are central to the treatment of
stable COPD (GOLD 2013). Short-acting bronchodilators,
such as salbutamol (a b2-adrenoceptor agonist) and iprat-
ropium (an anticholinergic), are recommended for use, as
needed, by patients with mild COPD. Regular use of long-
acting bronchodilators is recommended for moderate
and more severe COPD. These include the long-acting
b2-adrenoceptor agonists (LABAs) salmeterol and formo-
terol, which require twice-daily administration, and the
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muscarinic antagonist tiotropium, which is taken once daily
(Fang et al. 2011).
Indacaterol maleate is a novel, inhaled ultra-LABA that
provides 24-h bronchodilation with a fast onset of action
from the first dose and once-daily dosing in patients with
COPD (Cazzola et al. 2005; Kinoshita et al. 2012; Dahl
et al. 2010; Kornmann et al. 2011). Once-daily treatment
with indacaterol provided a significantly greater broncho-
dilator effect than currently marketed LABAs such as
formoterol (Foradil) and salmeterol (Serevent) and was
at least as effective in improving symptoms and health
status (Dahl et al. 2010; Kornmann et al. 2011). Indacaterol
is formulated as inhalation powder hard capsules for pul-
monary administration and delivered using a single-dose
dry-powder inhaler (SDDPI), the Breezhaler (EU), Neo-
haler (US) (Onbrez and Arcapta, respectively). This
device has a low air-flow resistance to ensure that patients
with severe lung conditions are able to use the device
effectively (Pavkov et al. 2010; Feldman et al. 2010).
Breezhaler has been shown to deliver a consistent dose
irrespective of disease severity and age, with no reported
device failures in clinical trials (Feldman et al. 2010).
Indacaterol has been approved for use in the mainte-
nance treatment of patients with COPD at doses ranging
from 75 to 300 lg once daily in 85 countries worldwide,
including China, Japan, the United States of America, and
the European Union. The pharmacokinetics of indacaterol
have been comprehensively characterized in Caucasian and
Japanese patients with COPD and healthy volunteers
(Hosoe et al. 2011; EU SMPC).
This is the first study that has been designed to deter-
mine the pharmacokinetics, safety, and tolerability of
multiple daily inhaled doses of indacaterol in healthy
Chinese volunteers.
The primary objective of the present study was to
characterize the serum pharmacokinetics (PK) of indaca-
terol in healthy Chinese volunteers following single and
repeated once daily inhaled administration of indacaterol
150 and 300 lg delivered via an SDDPI. Further objectives




This was a single center, randomized, double-blind, mul-
tiple-dose, parallel group study, using a placebo control
and two doses of indacaterol 150 and 300 lg. The study
protocol and all amendments of the study were reviewed
and approved by the Independent Ethics Committee of
Peking Union Medical College Hospital, Beijing, China.
The study was conducted according to the ethical princi-
ples of the Declaration of Helsinki. Written and signed
informed consent was obtained from each subject before
any study-specific screening procedures were performed.
2.2 Study population and randomization
Healthy male and female Chinese subjects aged between
18 and 45 years (incl.) and weighing at least 50 kg with a
body mass index within the range of 18–27 kg/m2 were
included in the study. Subjects were defined as Chinese if
they had both parents and grandparents of Chinese descent.
Exclusion criteria included any use of prescription drugs,
herbal supplements within 4 weeks prior to initial dosing
and/or over-the-counter medication or dietary supplements
(including vitamins) within 2 weeks prior to initial dosing;
pregnant or lactating women; and smokers who reported
cigarette use of more than 10 cigarettes per day. The study
randomized 32 subjects; 12 each into the two active
treatment groups, indacaterol 150 lg and indacaterol
300 lg, and eight to placebo for comparative safety
assessment. The designated randomization ratio was cho-
sen to maximize the number of subjects on each active dose
within the recommended 8–12 subjects per treatment group
requirement in China’s State Food and Drug Administra-
tion (SFDA) guidelines (SFDA 2005).
A single inhaled dose of indacaterol (150 or 300 lg) or
matching placebo was administered daily as single gelati-
nous capsules for 14 consecutive days in the morning,
using the Breezhaler device.
2.3 Bioanalytics
Pharmacokinetic venous blood samples were collected on
Days 1 and 14, at pre-dose, and at 0.08, 0.25, 0.5, 1, 2, 4, 8,
12, and 24 h post dose. Additional samples were collected
at 36, 48, 120, and 168 h post dose on Day 14. Trough
pharmacokinetic blood samples were collected on Days 7,
10, and 12 before dosing. All blood samples were collected
into silica-coated polypropylene collection tubes and left to
clot at room temperature for 20 min. The samples were
then centrifuged at 2,500g for 10 min to separate the
serum. Serum samples were then stored at less than
-20 C in polypropylene tubes until analyzed.
Indacaterol concentrations in serum were determined by
high-performance liquid chromatography-mass spectrom-
etry with lower limit of quantification (LLOQ) of 0.01 ng/
mL using 100 lL of human serum.
2.4 Pharmacokinetic analysis
All subjects who provided at least one evaluable determi-
nation of Cmax and/or AUC0–24h on Day 1 and/or Day 14
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along with actual dose and sampling time information were
included in the pharmacokinetic data analysis.
The following pharmacokinetic parameters were deter-
mined for indacaterol: Cmax (maximum serum drug con-
centration), Tmax (time to reach Cmax), and AUC0–24h (area
under the serum drug concentration–time curve from time
0 to 24 h post dose) on Day 1; AUC0–24h,ss (the AUC
during a dosing interval (s = 24 h) at steady-state), Cmax,ss
(maximum steady-state serum drug concentration), Cmin,ss
(minimum steady-state serum drug concentration), Cav,ss
(average steady-state serum drug concentration), Tmax,ss
(time to reach Cmax at steady state), T1/2 (elimination half-
life associated with the terminal slope of a semi logarith-
mic concentration time curve), T1/2,acc (effective half-life
determined according to Boxenbaum and Battle (1995),
based on drug accumulation at steady state), CL/F (the total
body clearance), VZ/F (the apparent volume of distribution),
and Racc (accumulation ratio) after repeated once-daily
doses on Day 14.
Cmax, Tmax, AUC0–24h were determined on Day 1 while
on Day 14, AUC0–24h,ss, Cmax,ss, Cmin,ss, Cav,ss, Tmax,ss, T1/2,
T1/2,acc, CL/F, VZ/F, Racc were measured.
All parameters except Racc and T1/2,acc were calculated
using WinNonlin Professional (Version 5.2, Pharsight
Corp., Mountain View, California). Racc and T1/2,acc were
determined using SAS Professional, version 8.2. Racc was
calculated using AUC values obtained from a dosing
interval according to the following equation:
ðAUC024h; Day 14Þ=ðAUC024h; Day 1Þ
Effective half-life (T1/2,acc) was determined based on
drug accumulation at steady state and calculated according
to the following equation (Boxenbaum and Battle 1995):
T1=2;acc ¼ ln 2  s= ln½Racc=ðRacc  1Þ;
where s is the dosing interval and Racc is the AUC accu-
mulation ratio at steady state.
2.5 Safety and tolerability analysis
Safety and tolerability assessments included recording all
adverse events (AEs) and serious AEs. Additional safety
assessments included monitoring of vital signs, electro-
cardiogram (ECG) recordings, and study of blood chem-
istry, urinalysis, and hematology. AE data, laboratory data
for hematology, blood biochemistry, urinalysis, ECG
results, and measurements of vital signs were summarized
descriptively by treatment group.
2.6 Statistical analysis
The dose-normalized geometric mean ratio (300:150) for
all PK parameters was estimated by back transforming the
values of the estimated mean difference and 90 % confi-
dence interval of the 300- and 150-lg doses (that were
calculated using analysis of variance). Change from base-
line (0-h measurement on Day 1) in heart rate, QTcF,
serum potassium, and blood glucose were compared
between each dose of indacaterol and placebo at each post-
dose time point using an analysis of covariance model with
baseline as covariate. Geometric mean concentrations at
any given time point were only calculated if all individual
concentrations were CLLOQ. Summary statistics were
provided for all safety and tolerability data.
3 Results
3.1 Study population
A total of 32 volunteers were enrolled into the study, with
27 males (84.4 %) and 5 females (15.6 %). The demo-
graphic characteristics of the patients are shown in Table 1
and were well balanced across dosing groups. All 32 sub-
jects completed the study. There were no significant pro-
tocol deviations during the conduct of the study.
3.2 Pharmacokinetic results
Following the single or multiple dose inhaled administra-
tion of indacaterol 150 and 300 lg for 14 days, indacaterol
was absorbed rapidly following inhalation, with a median
time to reach peak serum concentrations of 15 min post-
dose (Table 2). A summary of the mean pharmacokinetic
parameters of indacaterol at each dose level and sampling
day is given in Tables 2 and 3, respectively.
Arithmetic mean serum concentration time profiles of
indacaterol for each dose level (i.e. 150 and 300 lg) and
sampling day (first dose, Day 1 and repeated dose, Day 14)
are shown in Figs. 1 and 2.
For Day 14, the geometric mean [% coefficient of var-
iation (CV)] of Cmax,ss was 0.28 (44.6) ng/mL for the
150-lg dose and 0.68 (23.8) ng/mL for the 300-lg dose
(Table 4). The corresponding values for AUC0–24h,ss were
2.36 (38.7) h ng/mL and 6.33 (25.4) h ng/mL, respectively
(Table 4). The mean AUC0–24h accumulation ratio (Day
14–Day 1) was calculated as 2.6 and 2.7 for the 150- and
300-lg doses, respectively (Table 3).
The trough concentrations increased up to Day 12 with
the mean (SD) trough values ranging from 0.0574 ng/mL
(19.6) on Day 7 to 0.0686 ng/mL (23.8) on Day 12 at
150 lg, and from 0.164 ng/mL (44.4) on Day 7 to
0.179 ng/mL (51.7) on Day 12 at 300 lg. However, there
was little change between Days 12 and 14, indicating that
the steady state was achieved after 12–14 days of daily
dosing (Fig. 3). The systemic exposure to indacaterol
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increased between 1.27- and 1.34-fold for the 150-and
300-lg doses (Table 4).
Based on the observed indacaterol AUC accumulation
ratio for each subject, the effective half-life (T1/2,acc) of
Table 1 Summary of patient demographics by treatment group
Indacaterol 150 lg (n = 12) Indacaterol 300 lg (n = 12) Placebo (n = 8) Total (n = 32)
Age, years 28.3 (4.79) 24.8 (4.09) 26.4 (6.48) 26.5 (5.09)
Male/female (%) 83.3/16.7 83.3/16.7 87.5/12.5 84.4/15.6
Ethnicity (Chinese) (%) 100 100 100 100
Weight (kg) 65.5 (7.79) 61.8 (8.19) 63.0 (8.69) 63.5 (8.06)
Height (cm) 168.0 (7.53) 169.0 (6.30) 166.0 (5.60) 168.0 (6.51)
BMI (kg/m2) 23.3 (1.85) 21.6 (2.42) 22.8 (2.70) 22.5 (2.34)
Data are mean (SD), except male/female and ethnicity which are %
BMI body mass index, SD standard deviation
Table 2 Pharmacokinetic parameters of indacaterol following a
single dose of inhaled administration of indacaterol 150 and 300 lg
on Day 1 in healthy Chinese subjects
Indacaterol
Pharmacokinetic variable 150 lg (n = 12) 300 lg (n = 12)
Cmax (ng/mL) 0.206 (0.0568) 0.518 (0.0780)
Tmax (h) 0.25 (0.25–1.00) 0.25 (0.25–0.25)
AUC0–24h (h ng/mL) 0.974 (0.252) 2.43 (0.408)
Data are expressed as mean (SD), except for Tmax which are expressed
as median (min–max)
AUC0–24h,ss area under curve during a dosing interval (s = 24 h) at
steady-state, Cmax maximum serum drug concentration, Tmax time to
reach Cmax
Table 3 Pharmacokinetic parameters of indacaterol following mul-
tiple doses of inhaled administration of indacaterol 150 and 300 lg
for 14 days in healthy Chinese subjects
Pharmacokinetic variable Indacaterol
150 lg (n = 12) 300 lg (n = 12)
Cmax,ss (ng/mL) 0.299 (0.116) 0.697 (0.168)
Cmin,ss (ng/mL) 0.0645 (0.0311) 0.182 (0.0503)
Cav,ss (ng/mL) 0.105 (0.0381) 0.272 (0.0685)
Tmax,ss (h) 0.25 (0.25–0.50) 0.25 (0.25–0.50)
AUC0–24h,ss (h ng/mL) 2.51 (0.914) 6.52 (1.64)
Racc 2.59 (0.636) 2.69 (0.534)
T1/2acc (h) 33.9 (11.0) 35.8 (9.06)
CL/F (L/h) 67.9 (25.6) 48.7 (12.0)
Vz/F (L) 11050 (3506) 8153 (3023)
T1/2 (h) 116 (19.3) 118 (38.9)
Data are mean (SD) except for Tmax which are median (min–max)
AUC0-24h,ss area under curve during a dosing interval (s = 24 h) at
steady-state, Cmax,ss maximum steady-state serum drug concentration,
Cmin,ss minimum steady-state serum drug concentration, Cav,ss average
steady-state serum drug concentration, Tmax,ss time to reach Cmax at
steady state, T1/2 elimination half-life, T1/2,acc effective half-life based
on drug accumulation at steady state, CL/F, the total body clearance,
VZ/F the apparent volume of distribution, Racc accumulation ratio
Fig. 1 Arithmetic mean (SD) serum concentration–time profile
following single dose inhaled administration of indacaterol 150 and
300 lg on Day 1 in healthy Chinese subjects
Fig. 2 Arithmetic mean (SD) serum concentration–time profile
following multiple doses inhaled administration of indacaterol 150
and 300 lg for 14 days in healthy Chinese subjects
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indacaterol was determined for the 150- and 300-lg doses.
The mean (SD) of T1/2,acc was 33.9 (11.0) and 35.8 (9.06)
hours, respectively. After 14 days of once-daily dosing, the
mean terminal elimination half-lives were 116 and 118 h,
respectively.
3.3 Safety results
There were no meaningful differences between screening,
baseline, and end-of-study vital signs. Individual values
were almost entirely within the ranges specified for inclu-
sion in the study and there were no deviations that were of
clinical significance.
The overall incidence of AEs by preferred term is pre-
sented in Table 4. Most AEs were transient and mild in
severity. The most frequently reported AE was cough [56
(98.2 %) subjects; 150 lg (n = 6), 300 lg (n = 8), pla-
cebo (n = 1)]. This event was suspected to be dose related
although it also occurred in one patient receiving placebo.
One volunteer from the indacaterol 300 lg treatment arm
reported epistaxis as an AE. No deaths or serious adverse
events were reported. There were no clinically meaningful
differences in least squares (LS) mean serum potassium or
serum glucose all post-dose time-points for all treatments
compared to placebo on Days 1 and 14. There were dose-
dependent increases in heart rate and QTcF interval which
were consistent with the known effects of Indacaterol and
not considered to be clinically meaningful.
4 Discussion
While the pharmacokinetics of indacaterol have been previ-
ously extensively studied in Caucasian and Japanese patients
(Hosoe et al. 2011; EU SMPC) and healthy volunteers
(Khindri et al. 2011), this is the first study to evaluate the
pharmacokinetics of indacaterol following administration of
single and repeated once-daily doses of 150 and 300 lg in
healthy Chinese volunteers. Following single (Day 1) and
repeated (Day 14) inhalation, indacaterol was rapidly
absorbed into the systemic circulation with the median time to
maximum serum concentrations (Tmax) occurring 15 min
post inhalation for both doses. The early serum concentration
peak is likely to reflect absorption via the lung indicating that
a significant portion of the orally inhaled drug is delivered to
and systemically absorbed via the target organ for topical
COPD therapy. The systemic exposure to indacaterol, as
characterized by AUC0–24h and Cmax, increased in a dose-
proportional manner with moderate accumulation upon
repeated once-daily dosing as shown by the estimated AUC
accumulation ratios of 2.6 and 2.7 for the 150- and 300-lg
dose groups which was within the range seen for indacaterol
in other studies (Hosoe et al. 2011).
The disposition kinetics of indacaterol is multiphasic as
shown by the mean concentration–time profiles in Fig. 1.
Systemic concentrations decreased rapidly within the first
4–8 h after inhalation, and more slowly thereafter. The
concept of an effective half-life (T1/2,acc) of drug accumu-
lation as proposed by Boxenbaum and Battle (1995), was
applied to the data. In principle the effective half-life
reflects the actual observed drug accumulation, as opposed
to one or more aspects of exponential drug disposition, and
is calculated from the AUC accumulation ratio and the
dosing interval. The mean (SD) T1/2,acc values determined
for the 150- and 300-lg doses on Day 14 were 33.9 (10.9)
Table 4 Summary statistics for dose-proportionality evaluation of indacaterol 150 and 300 lg for Days 1 and 14
Day Pharmacokinetic variable Unit Geometric mean (%CV) Ratio of dose normalized geometric means (300 lg:150 lg)
150 lg 300 lg Estimate Lower 90 % CL Upper 90 % CL
1 AUC0–24h h ng/mL 0.94 (28.0) 2.39 (17.2) 1.27 1.08 1.49
Cmax ng/mL 0.20 (28.8) 0.51 (15.8) 1.29 1.10 1.51
14 AUC0–24h,ss h ng/mL 2.36 (38.7) 6.33 (25.4) 1.34 1.07 1.68
Cmax,ss ng/mL 0.28 (44.6) 0.68 (23.8) 1.23 0.96 1.56
AUC0–24h area under curve during a dosing interval (s = 24 h) at steady-state, Cmax maximum steady-state serum drug concentration, ss steady
state
Fig. 3 Arithmetic mean (SD) serum trough concentrations after
multiple doses inhaled administration of indacaterol 150 and 300 lg
in healthy Chinese subjects
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and 35.8 (9.1) hours, respectively. The mean (SD) terminal
elimination half-life (T1/2) values were 116 (19.3) and 118
(39.0) hours for 150 and 300 lg, respectively, on Day 14.
In this study, the indacaterol steady state was achieved
between 12 and 14 days of daily dosing. Indacaterol was
detectable in serum immediately after inhalation. The ratio
(300–150 lg) of the dose-normalized geometric means for
Cmax and AUC0–24h on Days 1 and 14 was above 1.0 and ranged
from 1.23 to 1.34, indicating that exposure to indacaterol
increased more than twofold between the 150- and 300-lg
doses. Given the fact that this study was not powered to assess
dose proportionality, the observed small deviations from dose-
proportionality appeared not to be clinically meaningful.
The finding that systemic concentrations of indacaterol
rapidly decline to very low levels may be advantageous for
the drug’s safety profile, since there is little risk of sus-
tained high systemic concentrations and/or significant drug
accumulation during chronic dosing. The dissociation
between the short residence time in the systemic circulation
and the long duration of action of indacaterol (Hosoe et al.
2011; Khindri et al. 2011; Moen 2010) might be related to
the fact that local drug load in the lung is required for
maintenance of bronchodilation effect in the lung whilst
systemic drug concentrations have little or no relevant
contribution to the bronchodilator effect.
Multiple, daily inhaled doses of indacaterol in healthy
Chinese subjects were well tolerated and had an acceptable
safety profile. There were no serious or unexpected AEs.
Cough was the most commonly observed treatment-related
adverse event, consistent with previous clinical studies
(Kinoshita et al. 2012; Dahl et al. 2010; Kornmann et al.
2011) as well as observations in healthy subjects from
other Asian ethnic populations (Khindri et al. 2011).
5 Conclusions
In conclusion, the once-daily dosing of inhaled indacaterol in
healthy Chinese volunteers produced a consistent and pre-
dictable pharmacokinetic profile. Indacaterol was systemi-
cally available shortly after inhalation. Systemic exposure to
indacaterol increased in a dose-proportional manner from
150 to 300 lg doses, with moderate accumulation upon
repeated once-daily dosing. Multiple inhaled doses of ind-
acaterol 150 and 300 lg (for 14 days) were also found to be
safe and well tolerated in healthy Chinese volunteers.
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